Aarey Drugs to hold 36th AGM on Sep 30, 2026, for FY26 results and RPT approval
Aarey Drugs & Pharmaceuticals Limited will hold its 36th AGM on September 30, 2026, to approve FY26 financial results and related party transactions for FY27. E-voting is open from Sep 27-29, 2026, with a cut-off date of Sep 23, 2026. Related party transaction limits proposed include up to ₹45 Cr with Enam Organics India Ltd.
The approval of related party transactions, especially those involving loans and advances up to substantial amounts, can have a material impact on the company's financial dealings and governance.
The announcement is a routine corporate event (AGM) and related party transaction approval, with no significant positive or negative financial news or strategic shifts highlighted.
Aarey Drugs & Pharmaceuticals Limited has announced its 36th Annual General Meeting (AGM) will be held on Wednesday, September 30, 2026, at 03:00 P.M. through Video Conferencing (VC) / Other Audio-Visual Means (OAVM). The meeting will consider and adopt the audited financial statements for the financial year 2025-26, along with the Directors' and Auditors' reports. Additionally, Mrs. Bina Ghatalia, who retires by rotation, will be considered for re-appointment as a Director.
The AGM will also seek approval for related party transactions for the financial year 2026-27. The proposed maximum aggregate value of transactions with various related parties includes office rent, loans/advances, and interest income. Notably, the company proposes a maximum of ₹45 Crores for loans/advances, repayment thereof, and interest income with Enam Organics India Ltd., and ₹30 Crores with Worth Investment & Trading Co. Ltd. Other related parties have proposed transaction limits ranging from ₹15 Crores.
E-voting will commence on September 27, 2026, at 09:00 AM and conclude on September 29, 2026, at 05:00 PM. The cut-off date for e-voting eligibility is September 23, 2026.
What to do with a filing like this
Aarey Drugs & Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under agm. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Aarey Drugs & Pharmaceuticals Limited. Read the original for the full detail.